Fatty Liver – NASH

Official Title

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

Study Summary

NASH is an acronym that stands for Non-Alcoholic SteatoHepatitis. It is the most severe form of non-alcoholic fatty liver disease (NAFLD), and is characterized by the presence of an abnormal accumulation of fat in the liver. It is heavily influenced by lifestyle; risk factors include: high blood pressure, obesity, type 2 diabetes, high cholesterol, insulin resistance, and metabolic syndrome. It may lead to complications such as cirrhosis and liver cancer. The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH.

Eligibility and Recruitment Information

Eligible Genders Both
Eligible Ages 18-100
Inclusion NASH (Non-alcoholic Steatohepatitis), BMI above 27, elevated liver enzymes, and MRI compatible
Exclusion Cancer in the past 5 years, gastric surgery, cirrhosis, or heart issues
Start Date
Compensation Variable
Location Orlando, FL, The Villages, FL

Study Information

Condition NASH

Administrative Information

Study ID NCT02855164

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.